<DOC>
	<DOCNO>NCT01285219</DOCNO>
	<brief_summary>Neutropenia one frequent adverse effect chemotherapy , main factor limit dosage delay schedule chemotherapy . Preventive filgrastim administration long establish standard care . A pegylated filgrastim independently develop GeneLeuk Biopharmaceutical Co. , Ltd , Shandong , China . It compose filgrastim 20 kd polyethylene glycol molecule covalently bound N-terminal residue . Preclinical study phase 1 phase 2 trial show pegylated filgrastim decrease renal clearance , increase plasma half-life , prolong efficacy compare ﬁlgrastim . These character similar Neulasta . The investigator design multicenter , randomize , cross-over phase Ⅲ trial compare efficacy safety single injection pegylated filgrastim daily injection ﬁlgrastim chemotherapy naive patient receive commonly use regimen . The hypothesis pegylated filgrastim similarly effective safe regular filgrastim .</brief_summary>
	<brief_title>A Study Comparing Pegylated Filgrastim Filgrastim Support Chemotherapy</brief_title>
	<detailed_description>This multicenter , randomize , open-label , cross-over , noninferiority study evaluate whether single injection pegﬁlgrastim effective safe daily injection ﬁlgrastim patient receive commonly use chemotherapy regimen . Patients randomly assign 1:1 ratio AOB BOA arm center stratiﬁcation variable . All patient receive two cycle chemotherapy identical regimen dosage . In arm AOB , patient administer pegylated filgrastim 100 ug/kg cycle 1 ﬁlgrastim 5 ug/kg/d cycle 2 ; arm BOA , patient receive ﬁlgrastim 5 ug/kg/d cycle 1 pegylated filgrastim 100 ug/kg cycle 2 . Study drug Both filgrastim pegylated filgrastim provide GeneLeuk Biopharmaceutical Co. , Ltd , Shandong , China . In cycle 1 AOB arm cycle 2 BOA arm , 9 day 3 , patient receive dose 100µg/kg pegylated filgrastim , base actual body weight , single s.c. injection . In cycle 2 AOB arm cycle 1 BOA arm , patient receive daily s.c. injection filgrastim dose 5 µg/kg/day . Injections begin 9 day 3 continue daily absolute neutrophil count ( ANC ) ≥10.0 × 109 /l document expect nadir maximum 14 day , whichever occur first . Chemotherapy Treatment All cytotoxic agent administrate day 1 21-day regimen . The regimen include PC ( paclitaxel 175 mg/m2 ; carboplatin area curve [ AUC ] 5～6 cisplatin 75 mg/m2 ) ； AC ( doxorubicin [ pirarubicin ] 60 mg/m2 epirubicin 100 mg/m2；cyclophosphamide 600 mg/m2 ) , PA ( paclitaxel 175 mg/m2 ；doxorubicin [ pirarubicin ] 50 mg/m2 epirubicin 80 mg/m2）； CHOP ( cyclophosphamide 750mg/m2；doxorubicin [ pirarubicin ] 50 mg/m2 epirubicin100 mg/m2；vincristine1.4 mg/m2；prednisone 100mg，po，day 1-5 ) 。 Efficacy measurement Blood sample collect complete blood count ( cbc ) differential day 0 , 3 , 5 , 7 , 9 , 11 , 13 , 17 21 cycle . Day 0 define day day one , cycle 1 base line , cycle 2 day 21 cycle 1 . The primary efficacy end point protective rate grade 4 neutropenia chemotherapy ( defined rate ANC keep 0.5 × 109 /l whole cycle ) . The secondary efficacy end point include rate grade 3/4 neutropenia , time neutrophil recovery ( deﬁned time chemotherapy administration patient 's ANC increase 2.0 × 109/l expect nadir ) , incidence febrile neutropenia ( define ANC &lt; 0.5×109/L auxiliary temperature &gt; 38.0℃ ) , incidence antibiotic administration ANC profile . Safety assessments Patients record auxiliary temperature daily , monitor adverse event throughout study . Before chemotherapy third week chemotherapy cycle , serum hepatic renal function , electrolysis , urine routine test electrocardiograph examine . The safety endpoint study incidence severity adverse event ( WHO grade 1-4 ) , side effect , change clinical laboratory value .</detailed_description>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>diagnosis malignant solid tumour ( exclude highly aggressive lymphoma lymphoblastic lymphoma Burkitt lymphoma ) chemotherapy naive Karnofsky Performance Status ≥70 age 1870 year ; normal white blood cell ( WBC ) count platelet count adequate renal , hepatic cardiac function life expectancy ≥3 month normal bone marrow function history systematic chemotherapy ( include adjuvant therapy ) large area radiotherapy ( &gt; 25 % bone marrow volume ) uncontrolled infection bone marrow involvement pregnancy , lactation history blood stem cell organ transplantation antibiotic administration within 72 hour enrolment long time exposure glucocorticoid immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Granulocyte colony-stimulating factor , recombinant</keyword>
	<keyword>Polyethylene glycol</keyword>
	<keyword>Neutropenia</keyword>
	<keyword>Drug therapy , combination</keyword>
</DOC>